Wilson Sonsini Goodrich & Rosati represents Pacific Biosciences of California, Inc. on the transaction. Pacific Biosciences of California, Inc. (PacBio) (NASDAQ: PACB), a leading developer of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Iambic Therapeutics on the transaction. Iambic Therapeutics (Iambic), a clinical-stage biotechnology company, announced the closing of an oversubscribed $50 million...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction. Iambic Therapeutics announced the closing of an oversubscribed $100 million Series B financing. The round was co-led by...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is representing Pacific Biosciences, and Fenwick & West is representing Apton Biosystems in the transaction. 8Pacific Biosciences of California (NASDAQ: PACB) (PacBio) announced...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised PacBio in the offering. Pacific Biosciences of California, Inc. (PacBio) (NASDAQ: PACB) announced that it has entered into a privately negotiated...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Pacific Biosciences of California on the offering, and Davis Polk advised the representatives of the several underwriters involved. Pacific Biosciences of California Inc. announced...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Nalu Medical on the deal. Nalu Medical, Inc., a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised 1859, Inc. on the deal. 1859, Inc., a platform company combining artificial intelligence and empirical pico-scale screening data at scale...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati, P.C. advised Nautilus Biotechnology, while Kirkland & Ellis LLP, working alongside Ogier, advised Arya III on the deal. Latham & Watkins...
You must be a Standard 1 Year member to access this content.
